Drug Profile
Cevoglitazar
Alternative Names: LBM 642Latest Information Update: 03 Dec 2008
Price :
$50
*
At a glance
- Originator Novartis
- Class Carboxylic acids; Indoles; Oxazoles; Sulfonamides
- Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists; Peroxisome proliferator-activated receptor gamma agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Diabetes mellitus; Lipid metabolism disorders
Most Recent Events
- 31 Dec 2007 Discontinued - Phase-II for Lipid metabolism disorders in Switzerland (unspecified route)
- 22 May 2007 LBM 642 is still in active development
- 03 Feb 2005 Phase-I clinical trials in Metabolic syndrome in Switzerland (unspecified route)